ID   NUOC-1-A2
AC   CVCL_IZ37
SY   Newcastle University Ovarian Cancer-1-A2
DR   Wikidata; Q54931177
RX   PubMed=28460465;
CC   Characteristics: Established from a mixed ovarian carcinoma of the right ovary which was 80% endometrioid, 15% clear cell and 5% high grade serous (HGS).
CC   Doubling time: 58 hours (Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=28460465).
CC   Omics: SNP array analysis.
CC   Miscellaneous: Doubling time from personal communication of Edmondson, Richard J.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=28460465
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 8
ST   D16S539: 9,13
ST   D5S818: 11
ST   D7S820: 7,8
ST   TH01: 7,8
ST   TPOX: 9,11
ST   vWA: 15
DI   NCIt; C7700; Ovarian adenocarcinoma
DI   ORDO; Orphanet_213504; Adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_IZ35 ! NUOC-1
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 15-05-17; Last updated: 19-12-24; Version: 11
//
RX   PubMed=28460465; DOI=10.18632/oncotarget.15821; PMCID=PMC5432300;
RA   McCormick A., Earp E., Elliot K., Cuthbert G., O'Donnell R.L.,
RA   Wilson B.T., Sutton R., Leeson C., Thomas H.D., Blair H.J.,
RA   Fordham S., Lunec J., Allan J., Edmondson R.J.;
RT   "Functional characterisation of a novel ovarian cancer cell line,
RT   NUOC-1.";
RL   Oncotarget 8:26832-26844(2017).
//